Analyst Ratings January 30, 2026

H.C. Wainwright Boosts Praxis Precision Medicines Target to $1,245, Citing Strong Clinical and Commercial Outlook

Analyst raises peak sales assumptions for key candidates as company readies NDAs and late-stage catalysts

By Marcus Reed PRAX
H.C. Wainwright Boosts Praxis Precision Medicines Target to $1,245, Citing Strong Clinical and Commercial Outlook
PRAX

H.C. Wainwright increased its price target for Praxis Precision Medicines Inc. (PRAX) to $1,245 from $340 while keeping a Buy rating, citing higher peak sales expectations for ulixacaltamide and relutrigine. The firm highlights relutrigine as a potential broad-use therapy with projected peak sales of $6.8 billion and points to forthcoming clinical readouts and NDA timelines as important catalysts. Praxis has shown rapid revenue growth and substantial share gains in 2025, but the stock is trading above fair value and carries notable volatility.

Key Points

  • H.C. Wainwright increased its price target on Praxis Precision Medicines to $1,245 from $340 and kept a Buy rating, citing higher peak sales estimates for ulixacaltamide and relutrigine.
  • Relutrigine is now projected to reach peak sales of $6.8 billion and is characterized as a potential "workhorse" therapy for multiple DEE variants; the EMERALD readout and possible NDA timing are key upcoming catalysts.
  • Praxis has posted rapid revenue growth and significant share gains in 2025, though the stock is trading above fair value and displays high volatility - implications for biotech and healthcare market participants and investors.

H.C. Wainwright has raised its price target on Praxis Precision Medicines Inc. to $1,245.00 from $340.00 and maintained a Buy rating on the shares. The new target implies a substantial upside versus the current market price of $314.28, even as market data indicates the stock is trading above its fair value.

The research firm's upgrade hinges on materially higher peak sales forecasts for Praxis' two lead drug candidates, ulixacaltamide and relutrigine. In particular, relutrigine is now modeled to reach peak sales of $6.8 billion. H.C. Wainwright described relutrigine as likely to serve as a "workhorse" therapy for patients with a range of developmental epileptic encephalopathies (DEEs), extending beyond the initially targeted SCN2A and SCN8A variants.

H.C. Wainwright also emphasized near-term clinical and regulatory milestones it sees as underappreciated by some investors. The firm pointed to the planned EMERALD study readout for relutrigine, expected before the end of 2026, and a potential New Drug Application (NDA) filing in early 2027 as notable catalysts that could influence the company’s valuation.

Praxis has posted striking top-line momentum, with revenue expanding 364.98% over the last twelve months. That growth accompanies strong share performance in 2025, with shares up 283% year-to-date versus the XBI biotech ETF’s 35% advance. Over the last year the stock has returned 312.44% and is trading close to its 52-week high of $326.91. The shares exhibit a high beta of 2.88, underscoring elevated volatility and corresponding risk-return dynamics for investors.

Management is advancing multiple regulatory and commercial preparations. Praxis has said it intends to submit two NDAs to the U.S. Food and Drug Administration by mid-February 2026: one for ulixacaltamide in essential tremor and one for relutrigine in SCN2A/8A developmental and epileptic encephalopathies. Both candidate therapies have received Breakthrough Therapy Designation from the FDA.

Market analysts beyond H.C. Wainwright have also adjusted views on Praxis. Piper Sandler raised its price target from $450 to $1,200 while maintaining an Overweight rating, signaling confidence in the company's potential. The same firm was also reported to have reiterated an Overweight rating with a $450 price target in another note.

Praxis has been active on the leadership and governance front as it prepares for late-stage development and potential commercial launches. The company appointed Dr. Orrin Devinsky as Head of Clinical Strategy. It also added Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and elevated Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. Company statements describe these moves as part of preparations for commercial launch planning and for supporting late-stage program activities.

H.C. Wainwright’s dramatically higher target reflects optimism about commercial potential and clinical progress, but the stock’s valuation metrics and high volatility suggest investors should weigh both upside and downside scenarios tied to trial readouts, regulatory timing, and commercial execution.


Context and near-term timeline

  • Planned NDA submissions by mid-February 2026 for ulixacaltamide (essential tremor) and relutrigine (SCN2A/8A DEEs).
  • EMERALD study readout for relutrigine expected before year-end 2026, with a potential NDA filing in early 2027 as a follow-up catalyst.

Market performance and metrics

  • Current share price cited at $314.28 and trading near a 52-week high of $326.91.
  • Reported revenue growth of 364.98% in the last twelve months.
  • Share gains of 283% during 2025 versus a 35% rise in the XBI biotech ETF; 312.44% return over the past year; beta of 2.88 indicating pronounced volatility.

Risks

  • The stock is trading above its fair value and has a high beta of 2.88, indicating elevated price volatility that could affect investor returns - relevant to equity investors and portfolio managers.
  • Clinical and regulatory timelines are pivotal - the EMERALD readout, NDA filing windows and FDA decisions create execution risk for the company and influence biotech sector valuations.
  • Significant recent share appreciation (283% in 2025 and a 312.44% one-year return) may leave limited near-term upside absent successful trial readouts or approvals, increasing downside risk for speculative investors.

More from Analyst Ratings

JPMorgan Lifts Chevron Price Target to $181, Citing Cost Cuts and Post-Merger Investment Phase Feb 2, 2026 H.C. Wainwright Sticks With Buy on Summit Therapeutics After FDA Accepts BLA Feb 2, 2026 Mizuho Lifts AXIS Capital Target After Strong 2025 Momentum Feb 2, 2026 JPMorgan Lifts ExxonMobil Target to $140 After Strong Q4 Results; Stock Near 52-Week High Feb 2, 2026 JPMorgan Reaffirms Overweight on Carvana, Cites Durable Online Advantage Feb 2, 2026